tiprankstipranks
Trending News
More News >
DSM-Firmenich AG (NL:DSFIR)
:DSFIR
Netherlands Market
Advertisement

DSM-Firmenich AG (DSFIR) AI Stock Analysis

Compare
10 Followers

Top Page

NL:DSFIR

DSM-Firmenich AG

(DSFIR)

Rating:60Neutral
Price Target:
€85.00
▲(1.80% Upside)
DSM-Firmenich AG's overall stock score is primarily driven by its solid financial performance, which indicates strong cash flow and profitability improvements. However, technical analysis shows bearish signals, and the high P/E ratio suggests potential overvaluation. The absence of earnings call and corporate event insights limits additional context.

DSM-Firmenich AG (DSFIR) vs. iShares MSCI Netherlands ETF (EWN)

DSM-Firmenich AG Business Overview & Revenue Model

Company DescriptionDSM-Firmenich AG, a science-based company, engages in beauty, health, and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Perfumery & Beauty; Animal Nutrition & Health (ANH); Health, Nutrition & Care (HNC); and Food & Beverage segments. The Perfumery & Beauty offers perfumery and aroma ingredients. The Animal Nutrition & Health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, personal care and aroma, and biomedical materials markets. It offers vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, and sunscreen filters, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise, and customized solutions. The Food & Beverage segment provides ingredients and solutions for use in a range of food products, such as dairy; bakery, cereals, and bars; savory food; beverages and brewing; confectionery and fruit; plant-based meat and fish alternatives; and petfood. The company was founded in 1902 and is headquartered in Kaiseraugst, Switzerland.
How the Company Makes MoneyDSM-Firmenich AG generates revenue through a diversified portfolio of products and services across its key segments. The company earns money by supplying essential ingredients and solutions to the food and beverage industry, including vitamins, nutritional supplements, and specialty food ingredients. It also produces fragrances and flavors for the personal care and household sectors. Additionally, DSM-Firmenich is involved in health and biosciences, providing solutions for medical nutrition and dietary supplements. Strategic partnerships and a strong focus on research and development also play crucial roles in driving the company's growth and profitability.

DSM-Firmenich AG Financial Statement Overview

Summary
DSM-Firmenich AG shows a positive trajectory with solid revenue growth and improved profitability metrics. The company's balance sheet is stable with manageable debt levels, and its cash flow generation remains strong, supporting ongoing investments and operations. Continued focus on profitability and debt management will be key to sustaining growth and stability in the future.
Income Statement
75
Positive
DSM-Firmenich AG has demonstrated strong revenue growth, with a CAGR of approximately 9% over the last five years. The gross profit margin stands at 33.2%, indicating efficient cost management. However, the company experienced a negative EBIT in 2023, impacting its EBIT margin. Net profit margin improved significantly to 1.95% in 2024 after a substantial loss in 2023, reflecting recovery efforts and operational improvements.
Balance Sheet
70
Positive
The balance sheet is robust with a strong equity base, evidenced by an equity ratio of 66.7% for 2024. The debt-to-equity ratio is moderate at 0.23, indicating prudent leverage use. Return on equity improved to 1.1% in 2024, showcasing an upward trajectory after earlier challenges. However, high total liabilities highlight a need for ongoing debt management.
Cash Flow
80
Positive
Cash flow from operations is solid, with a notable increase in free cash flow in 2024, growing by 71.8% from 2023. The operating cash flow to net income ratio is strong at 7.11, indicating robust cash generation relative to net profits. The free cash flow to net income ratio is favorable at 4.06, reflecting efficient capital expenditure management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue12.80B10.63B8.39B11.44B8.11B
Gross Profit4.25B2.61B2.78B4.19B2.78B
EBITDA561.00M822.00M1.31B859.00M1.21B
Net Income250.00M-652.00M460.00M872.00M448.00M
Balance Sheet
Total Assets33.75B34.27B17.61B16.02B14.35B
Cash, Cash Equivalents and Short-Term Investments2.72B2.56B2.88B2.05B914.00M
Total Debt5.28B4.83B3.06B3.05B3.54B
Total Liabilities11.05B11.20B6.71B6.62B6.86B
Stockholders Equity22.51B22.91B10.74B9.32B7.40B
Cash Flow
Free Cash Flow1.01B590.00M279.00M994.00M1.04B
Operating Cash Flow1.78B1.26B923.00M1.43B1.49B
Investing Cash Flow-252.00M-795.00M871.00M208.00M-1.48B
Financing Cash Flow-1.33B-820.00M-598.00M-984.00M83.00M

DSM-Firmenich AG Technical Analysis

Technical Analysis Sentiment
Negative
Last Price83.50
Price Trends
50DMA
86.85
Negative
100DMA
90.41
Negative
200DMA
93.21
Negative
Market Momentum
MACD
-0.79
Negative
RSI
43.50
Neutral
STOCH
33.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:DSFIR, the sentiment is Negative. The current price of 83.5 is above the 20-day moving average (MA) of 83.15, below the 50-day MA of 86.85, and below the 200-day MA of 93.21, indicating a neutral trend. The MACD of -0.79 indicates Negative momentum. The RSI at 43.50 is Neutral, neither overbought nor oversold. The STOCH value of 33.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:DSFIR.

DSM-Firmenich AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.26B6.130.71%2.93%3.45%-36.02%
60
Neutral
€22.04B30.67
2.99%4.46%
€10.09B24.319.60%
€784.41M88.521.94%
€1.84B9.795.98%
€23.38B9.544.81%
€1.03B59.30
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NL:DSFIR
DSM-Firmenich AG
83.50
-35.61
-29.90%
GB:0A00
Akzo Nobel NV
59.05
3.22
5.77%
GB:0LO9
AMG ADVANCED METALLURGICAL GROUP NV
26.30
11.82
81.63%
GB:0OLF
Aperam S.A.
26.01
2.31
9.75%
GB:0RP9
ArcelorMittal
28.50
7.66
36.76%
GB:0QGH
OCI N.V.
4.91
0.20
4.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025